ReviewDiabetes2025
Closing the Gap Between Vision and Victory in Type 1 Diabetes: The NIDDK Human Islet Research Network (HIRN) Initiative.
Review in Diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Virtual multiplex staining of the pancreatic islets across type 1 diabetes progression using a Schrödinger bridge.bioRxiv : the preprint server for biology · 2026Article
- NIDDK: Celebrating 75 Years of Advancing Diabetes Research.Diabetes care · 2025Article
- NIDDK: Celebrating 75 Years of Advancing Diabetes Research.Diabetes · 2025Article
- Article
- NIDDK at 75 Years of Age: Great Triumphs but Concerns for Its Longevity.Diabetes care · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The identification of a "rundlichen Häuflein" by Paul Langerhans more than 150 years ago marked the initiation of a global effort to unravel the mysteries of pancreatic islets, an intricate system of nutrient-sensing, hormone-secreting, and signaling cells. In type 1 diabetes, this interconnected network is vulnerable to malfunction and immune attack, with strategies to prevent or repair islet damage still in their infancy. In 2014, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established the Human Islet Research Network (HIRN) to accelerate our understanding of the molecular and cellular basis of type 1 diabetes development. In this article, investigators from the HIRN detail pioneering advances, technologies, and systems that contextualize insulin-producing β-cells and other related cells within their physiological environment. Disease models, devices, and therapies are evaluated by the HIRN in light of promising functional and mechanistic data. Collaborative relationships and opportunities within this network are emphasized as a means of enhancing the quality of innovative research and talent in science. Topics are developed through a series of questions, achievements, and milestones, with the 75th anniversary of the NIDDK as an opportunity to reflect on the past, present, and future of type 1 diabetes research. ARTICLE HIGHLIGHTS: The Human Islet Research Network (HIRN) was created by the National Institute of Diabetes and Digestive and Kidney Diseases to accelerate pioneering basic and translational research on the prevention, development, and progression of type 1 diabetes. There are critical knowledge gaps in research on the processes underlying human β-cell protection, loss, and replacement in type 1 diabetes. A multidisciplinary and collaborative research community focused on outstanding biological questions propels the development of innovative models, tools, and technologies and helps contextualize the complexity of this disease. Discoveries arising from the HIRN will profoundly improve our understanding of type 1 diabetes pathogenesis and expedite the development of disease avoidance, diagnosis, and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.